Here are the DEF 14A proxy statements from Oncolytics Biotech, Inc. (ONCY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ONCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCY filings page.
Oncolytics Biotech Inc. is seeking shareholder votes at its virtual 2026 annual meeting on November 19, 2026, on seven director nominees, ratification of Baker Tilly US, LLP for 2026, an advisory executive-compensation vote, and an advisory vote on how often that compensation vote should occur. Seven directors are to serve after the meeting, down from nine; Angela Holtham and Wayne Pisano are not standing for reelection. A submitted proxy without voting instructions defaults to votes for the nominees, auditor ratification and executive compensation, and a three-year say-on-pay frequency.
Jared Kelly became CEO on June 11, 2025, replacing interim CEO Wayne Pisano. The 2025 summary compensation table reports total compensation of $2,108,512 for Kelly. Oncolytics reported a net loss of $28.759 million in 2025, compared with $22.794 million in 2024. As of September 22, 2026, 131,120,719 common shares were outstanding and entitled to vote.